HBV Core-specific CD4+ T cells correlate with sustained viral control upon off-treatment in HBeAg-positive chronic hepatitis B patients

Aliabadi, 2022, Impact of HBsAg and HBcrAg levels on phenotype and function of HBV-specific T cells in patients with chronic hepatitis B virus infection, Gut, 71, 2300, 10.1136/gutjnl-2021-324646 Berg, 2017, Long-term response after stopping tenofovir disoproxil fumarate in non-cirrhotic HBeAg-negative patients - FINITE study, J. Hepatol., 67, 918, 10.1016/j.jhep.2017.07.012 Bertoletti, 2016, Adaptive immunity in HBV infection, J. Hepatol., 64, S71, 10.1016/j.jhep.2016.01.026 Boni, 2007, Characterization of hepatitis B virus (HBV)-Specific T-cell dysfunction in chronic HBV infection, J. Virol., 81, 4215, 10.1128/JVI.02844-06 Boni, 2012, Restored function of HBV-specific T cells after long-term effective therapy with nucleos(t)ide analogues, Gastroenterology, 143, 963, 10.1053/j.gastro.2012.07.014 García-López, 2021, Viral and immune factors associated with successful treatment withdrawal in HBeAg-negative chronic hepatitis B patients, J. Hepatol., 74, 1064, 10.1016/j.jhep.2020.11.043 Gehring, 2007, The level of viral antigen presented by hepatocytes influences CD8 T-cell function, J. Virol., 81, 2940, 10.1128/JVI.02415-06 Hoogeveen, 2022, Hepatitis B virus-specific CD4 T-cell responses differentiate functional cure from chronic surface antigen(+) infection, J. Hepatol., 10.1016/j.jhep.2022.05.041 Hoogeveen, 2019, Phenotype and function of HBV-specific T cells is determined by the targeted epitope in addition to the stage of infection, Gut, 68, 893, 10.1136/gutjnl-2018-316644 Jacobi, 2019, OX40 stimulation and PD-L1 blockade synergistically augment HBV-specific CD4 T cells in patients with HBeAg-negative infection, J. Hepatol., 70, 1103, 10.1016/j.jhep.2019.02.016 Kakimi, 2002, Immunogenicity and tolerogenicity of hepatitis B virus structural and nonstructural proteins: implications for immunotherapy of persistent viral infections, J. Virol., 76, 8609, 10.1128/JVI.76.17.8609-8620.2002 Li, 2023, Differential response of HBV Envelope-specific CD4+ T cells is related to HBsAg loss after stopping nucleos(t)ide analogue therapy, Hepatology Maini, 2000, The role of virus-specific CD8(+) cells in liver damage and viral control during persistent hepatitis B virus infection, J. Exp. Med., 191, 1269, 10.1084/jem.191.8.1269 Penna, 2012, Peginterferon-alpha does not improve early peripheral blood HBV-specific T-cell responses in HBeAg-negative chronic hepatitis, J. Hepatol., 56, 1239, 10.1016/j.jhep.2011.12.032 Ridruejo, 2014, Relapse rates in chronic hepatitis B naive patients after discontinuation of antiviral therapy with entecavir, J. Viral Hepat., 21, 590, 10.1111/jvh.12200 Rinker, 2018, Hepatitis B virus-specific T cell responses after stopping nucleos(t)ide analogue therapy in HBeAg-negative chronic hepatitis B, J. Hepatol., 69, 584, 10.1016/j.jhep.2018.05.004 Rivino, 2018, Hepatitis B virus-specific T cells associate with viral control upon nucleos(t)ide-analogue therapy discontinuation, J. Clin. Invest., 128, 668, 10.1172/JCI92812 Schuch, 2019, Phenotypic and functional differences of HBV core-specific versus HBV polymerase-specific CD8+ T cells in chronically HBV-infected patients with low viral load, Gut, 68, 905, 10.1136/gutjnl-2018-316641 Seto, 2018, Chronic hepatitis B virus infection, Lancet, 392, 2313, 10.1016/S0140-6736(18)31865-8 Sonneveld, 2022, Probability of HBsAg loss after nucleo(s)tide analogue withdrawal depends on HBV genotype and viral antigen levels, J. Hepatol., 76, 1042, 10.1016/j.jhep.2022.01.007 Swain, 2012, Expanding roles for CD4⁺ T cells in immunity to viruses, Nat. Rev. Immunol., 12, 136, 10.1038/nri3152 Tan, 2008, Host ethnicity and virus genotype shape the hepatitis B virus-specific T-cell repertoire, J. Virol., 82, 10986, 10.1128/JVI.01124-08 Thimme, 2003, CD8(+) T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection, J. Virol., 77, 68, 10.1128/JVI.77.1.68-76.2003 Wang, 2020, TNF-α/IFN-γ profile of HBV-specific CD4 T cells is associated with liver damage and viral clearance in chronic HBV infection, J. Hepatol., 72, 45, 10.1016/j.jhep.2019.08.024 Webster, 2004, Longitudinal analysis of CD8+ T cells specific for structural and nonstructural hepatitis B virus proteins in patients with chronic hepatitis B: implications for immunotherapy, J. Virol., 78, 5707, 10.1128/JVI.78.11.5707-5719.2004 Yang, 2010, Immune effectors required for hepatitis B virus clearance, Proc. Natl. Acad. Sci. U. S. A., 107, 798, 10.1073/pnas.0913498107